Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
SCYX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 08, 2026
Report Source: 2026 1st Quarter Report
SCYNEXIS Inc. Stock Analysis SCYX
United States Health Care Nano Cap Report: SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 18 full-time employees. The company went IPO on 2014-05-02. The firm's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Read More SCYNEXIS Inc (SCYX) Chart
Key Statistics of SCYNEXIS Inc (SCYX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$3.68Volume
76.80KP/E Ratio (TTM)
-52 Week Range
Market Cap
56.40MAvg. Volume
237.98KDividend Yield
-Financial Metrics & Statements of SCYNEXIS Inc (SCYX)
FAQ's for SCYNEXIS Inc (SCYX)
- According to Musaffa’s Shariah screening methodology, SCYNEXIS Inc (SCYX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes SCYNEXIS Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in SCYNEXIS Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of SCYNEXIS Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of SCYNEXIS Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of SCYNEXIS Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.